News zum Sektor Gesundheit aus Island

 

Announcement no. 52/2026 26 October 2026 Reykjavik, Iceland/Copenhagen, Denmark, 26 October 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 19 October to 23 October 2026 Embla Medical has acquired 51,000 shares under the Program at the average price of DKK 26.55. Following the transactions below, the Company holds 2,883,486 shares, corresponding to 0.67% of the...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Announcement no. 51/2026 Interim Report Q3 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q3 2026 were USD 250 million, representing 5% reported growth and 4% organic growth. Growth was driven by Prosthetics & Neuro Orthotics, with strong performance in EMEA, partially offset by softer results in Americas and APAC. Bracing & Supports delivered moderate growth, while Patient Care sales were flat in the quarter. In Patient Care, sales performance has been below the expectations we set at the beginning of the year. Mainly as significant integration effort has slowed...

Announcement no. 50/2026 19 October 2026 Reykjavik, Iceland/Copenhagen, Denmark, 19 October 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 12 October to 16 October 2026 Embla Medical has acquired 47,000 shares under the Program at the average price of DKK 27.65. Following the transactions below, the Company holds 2,832,486 shares, corresponding to 0.66% of the...

Announcement no. 49/2026 12 October 2026 Reykjavik, Iceland/Copenhagen, Denmark, 12 October 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 5 October to 9 October 2026 Embla Medical has acquired 18,124 shares under the Program at the average price of DKK 27.73. Following the transactions below, the Company holds 2,785,486 shares, corresponding to 0.65% of the...

Reykjavik, Iceland/Copenhagen, Denmark, 6 October 2026. Embla Medical (Nasdaq Copenhagen: EMBLA) will publish its Q3 2026 Report on October 20, 2026, at 7:00 CET. A conference call will be hosted on the same day at 9:00 CET / 7:00 GMT / 3:00am EST. The event will be hosted by Sveinn Solvason, President and CEO, and G. Arna Sveinsdottir, CFO. The call will include a review of the quarterly results and will be held in English. Slides used in the presentation will be made available on the company website at the following link: https://www.emblamedical.com/investors To participate in...

Announcement no. 48/2026 5 October 2026 Reykjavik, Iceland/Copenhagen, Denmark, 5 October 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 28 September to 2 October 2026 Embla Medical has acquired 45,263 shares under the Program at the average price of DKK 27.11. Following the transactions below, the Company holds 2,767,362 shares, corresponding to 0.65% of the...

Announcement no. 47/2026 28 September 2026 Reykjavik, Iceland/Copenhagen, Denmark, 28 September 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 21 September to 25 September 2026 Embla Medical has acquired 18,000 shares under the Program at the average price of DKK 27.34. Following the transactions below, the Company holds 2,722,099 shares, corresponding to 0.64%...

Announcement no. 46/2026 21 September 2026 Reykjavik, Iceland/Copenhagen, Denmark, 21 September 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 14 September to 18 September 2026 Embla Medical has acquired 36,868 shares under the Program at the average price of DKK 27.23. Following the transactions below, the Company holds 2,704,099 shares, corresponding to 0.63%...

Announcement no. 45/2026 14 September 2026 Reykjavik, Iceland/Copenhagen, Denmark, 14 September 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 7 September to 11 September 2026 Embla Medical has acquired 62,000 shares under the Program at the average price of DKK 28.13. Following the transactions below, the Company holds 2,667,231 shares, corresponding to 0.62%...

Announcement no. 44/2026 7 September 2026 Reykjavik, Iceland/Copenhagen, Denmark, 7 September 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 24 August to 4 September 2026 Embla Medical has acquired 94,630 shares under the Program at the average price of DKK 29.41. Following the transactions below, the Company holds 2,605,231 shares, corresponding to 0.61% of the...

Embla Medical bündelt sein breiteres Geschäft unter einem neuen Konzernnamen. Össur bleibt als Premiummarke für Prothetik und Orthesen erhalten. Formotion vereint das Klinikgeschäft. "Embla wandelt sich vom Prothesenhersteller zur globalen Mobilitätsgruppe", sagt IR-Chef Klaus Sindahl. Der Umsatz soll 2026 erstmals eine Milliarde US-Dollar überschreiten. Der Prothetikmarkt wächst jährlich um 6 bis 8 %. Embla investiert 7 bis 8 % des Umsatzes in Forschung. Das entspricht mehr als 50 Mio. Euro. Das Produktgeschäft wuchs zuletzt um 12 %. Patient Care verlor dagegen 2 %. Sindahl erklärt den Rückgang mit der Klinikintegration und Einzelereignissen in Schweden und Frankreich. "Wir erwarten in den kommenden Quartalen wieder Wachstum." Fast 200 Kliniken schaffen direkten Zugang zu Patienten. Im Markt sieht Sindahl zwei große, voll integrierte Anbieter. "Ottobock und wir sind seit vielen Jahren direkte Konkurrenten." Embla positioniert sich als klare Nummer zwei. Die Bilanz erlaubt laut Sindahl weiter...

Announcement no. 43/2026 24 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 24 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 17 August to 21 August 2026 Embla Medical has acquired 56,000 shares under the Program at the average price of DKK 29.71. Following the transactions below, the Company holds 2,510,601 shares, corresponding to 0.59% of the...

Announcement no. 42/2026 17 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 17 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 10 August to 14 August 2026 Embla Medical has acquired 50,246 shares under the Program at the average price of DKK 29.68. Following the transactions below, the Company holds 2,454,601 shares, corresponding to 0.57% of the...

Announcement no. 41/2026 10 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 10 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 3 August to 7 August  2026 Embla Medical has acquired 55,654 shares under the Program at the average price of DKK 28.91. Following the transactions below, the Company holds 2,404,355 shares, corresponding to 0.56% of the...

Announcement no. 40/2026 3 August 2026 Reykjavik, Iceland/Copenhagen, Denmark, 3 August 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 27 July to 31 July 2026 Embla Medical has acquired 47,000 shares under the Program at the average price of DKK 28.35. Following the transactions below, the Company holds 2,348,701 shares, corresponding to 0.55% of the Company's...

· The Nordic Investment Bank (NIB) has signed a EUR 50 million 7-year loan with Embla Medical hf.  · The financing will support the company's research and development activities during 2027–2029.  · The project contributes to innovation in the healthcare sector and the development of advanced medical technologies.   The investments focus on the development of new and improved prosthetics, orthotics and related healthcare solutions, including advances in materials, digital technologies and patient care.  “Innovation in medical technology plays an important role in improving quality...

Announcement no. 39/2026 28 July 2026 Reykjavik, Iceland/Copenhagen, Denmark, 28 July 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 37/2025 dated 17 July 2026. During the period 20 July to 24 July 2026 Embla Medical has acquired 66,500 shares under the Program at the average price of DKK 26.95. Following the transactions below, the Company holds 2,301,701 shares, corresponding to 0.54% of the Company's...

Announcement no. 38/2026 Interim Report Q2 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined. In Patient Care, we continue to see encouraging progress, with most of our clinics delivering increased productivity and...